Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €45.28 EUR
Change Today 0.00 / 0.00%
Volume 19.6K
DBV On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
Frankfurt
Frankfurt
As of 11:35 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

dbv technologies sa (DBV) Snapshot

Open
€45.30
Previous Close
€45.28
Day High
€45.49
Day Low
€44.97
52 Week High
04/9/15 - €53.47
52 Week Low
06/4/14 - €17.91
Market Cap
869.8M
Average Volume 10 Days
18.8K
EPS TTM
€-1.49
Shares Outstanding
19.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DBV TECHNOLOGIES SA (DBV)

Related News

No related news articles were found.

dbv technologies sa (DBV) Related Businessweek News

No Related Businessweek News Found

dbv technologies sa (DBV) Details

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company provides Diallertest Milk, a diagnostic product for the detection of cow’s milk protein allergy (CMPA) in children. Its products include Viaskin Peanut, an immunotherapy product for the treatment peanut allergies in children, adolescents, and adults; Viaskin Milk for the treatment of CMPA and milk-induced eosinophilic esophagitis (EoE); and Viaskin Egg, a development program for the treatment of hen’s egg allergy. The company also develops other earlier stage product development programs, which comprise house dust mites allergy, EoE, pertusiss boost vaccine, and birch pollen allergy. DBV Technologies S.A. was founded in 2002 and is based in Bagneux, France.

56 Employees
Last Reported Date: 04/29/15
Founded in 2002

dbv technologies sa (DBV) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: €427.7K
Compensation as of Fiscal Year 2014.

dbv technologies sa (DBV) Key Developments

DBV Technologies S.A. Reports Earnings Results for the First Quarter of 2014

DBV Technologies S.A. reported earnings results for the first quarter of 2014. For the first three months of 2015, the total income reached 1,453,706, up from 1,277,349 for the same period in 2014. This 13.8% increase partly resulted from an increase in Research Tax Credit, amounting to 1,275,595 over the period, compared to 1,227,140 a year earlier, and also from the sales of Diallertest, which amounted to 107,520 for the first three months of 2015, whilst no revenue was booked for the sales of Diallertest over the same period in 2014.

EnterNext Selects DBV Technologies to Enter its Tech 40 Label

DBV Technologies announced that it has been selected by EnterNext to become a member of the Tech 40 Index tier. Based on quantitative and qualitative criteria, this Euronext label is awarded on a yearly basis to the top 40 technology companies listed on the SME's tier of the Euronext exchange.

DBV Technologies S.A. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 08:40 AM

DBV Technologies S.A. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 08:40 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: David Schilansky, Chief Operating Officer, Susanna Mesa, Vice President of Finance, US Investor Relations & Strategy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DBV:FP €45.28 EUR 0.00

DBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ALK-Abello A/S kr823.00 DKK +2.00
Allergy Therapeutics PLC 21.38 GBp 0.00
Merck & Co Inc $59.38 USD -0.72
Sanofi €92.30 EUR -0.08
Stallergenes SA €55.84 EUR +0.04
View Industry Companies
 

Industry Analysis

DBV

Industry Average

Valuation DBV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 147.6x
Price/Book 6.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 142.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DBV TECHNOLOGIES SA, please visit www.dbv-technologies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.